ReviewHuman vaccines & immunotherapeutics2024
Pneumococcal disease burden in high-risk older adults: Exploring impact of comorbidities, long-term care facilities, antibiotic resistance, and immunization policies through a narrative literature review.
Review in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of pneumococcal vaccination in reducing hospitalization and mortality among the elderly: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2025Pooled it
- Immunogenicity and Safety of Co-administration of Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine With 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years: A Randomized, Non-inferiority Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Pneumococcal vaccination awareness and uptake among high-risk patients attending internal medicine outpatient clinics: A cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- Article
- Vaccinations in patients with interstitial lung diseases: a narrative review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Host, Pathogen, and Pulmonary Anatomy in Pneumonia: An Integrated Imaging and Clinical Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Post-Vaccination Surveillance of Invasive Pneumococcal Disease in Ghana.Diseases (Basel, Switzerland) · 2026Article
- A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Etiological landscape and co-infection dynamics in Acute Respiratory Infections (ARIs): insights from a multicenter outpatient study in Yunnan, China.BMC infectious diseases · 2026Article
- Article
- Aging and vaccines: impact of immunosenescence and inflammaging in vaccine response.Frontiers in aging · 2026Review
- Infectious diseases, infection control, vaccines and long-term care: an European interdisciplinary Council on ageing consensus document.Aging clinical and experimental research · 2025Review
- Erratum: Pneumococcal Vaccination of Adults in Italy: What Strategies?Journal of preventive medicine and hygiene · 2025Article
- Pneumococcal Vaccination of Adults in Italy: What Strategies?Journal of preventive medicine and hygiene · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to provide a comprehensive review of literature on pneumococcal disease burden in high-risk older adults aged ≥65 with focus on impact of comorbidities, long-term care facilities (LTCFs), antibiotic resistance, and vaccination policies across various countries. Research showed that the disease burden and the prevalence of antibiotic-resistant pneumococci was higher in the elderly, particularly those residing in LTCFs, and with comorbidities. These individuals are at high risk of infection with antibiotic-resistant serotypes 10A, 11A, and 15B. The vaccination strategies and national guidelines for pneumococcal vaccines in the elderly vary across countries. Some countries focus on single-dose strategies, while others recommend sequential vaccinations with varying intervals. Although vaccination policies are well-established for the elderly, they are not as well-established for high-risk elderly groups, and this review underscores the need for more tailored vaccination strategies for these groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.